Poul Jennum

Poul Jennum

Auto-generated profile, based on publicly available information

Poul Jennum

Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Sleep Medicine Reviews
Verified
Journal Article
Open access
PJPoul Jørgen Jennum
Poul Jørgen Jennum
GPGiuseppe Plazzi
Giuseppe Plazzi
Alessandro SilvaniAlessandro Silvani
Alessandro Silvani
LSLee A. Surkin
Lee A. Surkin
YDYves Dauvilliers
Yves Dauvilliers
Narcolepsy type 1 (NT1) is a lifelong disorder of sleep-wake dysregulation defined by clinical symptoms, neurophysiological findings, and low hypocretin levels. Besides a role in sleep, hypocretins are also involved in regulation of heart rate and blood pressure. This literature review examines data on the autonomic effects of hypocretin deficiency and evidence about how narcolepsy is associated with multiple cardiovascular risk factors and comorbidities, including cardiovascular disease. An important impact in NT1 is lack of nocturnal blood pressure dipping, which has been associated with mortality in the general population. Hypertension is also prevalent in NT1. Furthermore, disrupted nighttime sleep and excessive daytime sleepiness, which are characteristic of narcolepsy, may increase cardiovascular risk. Patients with narcolepsy also often present with other comorbidities (eg, obesity, diabetes, depression, other sleep disorders) that may contribute to increased cardiovascular risk. Management of multimorbidity in patients with narcolepsy should include regular assessment of cardiovascular health (including ambulatory blood pressure monitoring), mitigation of cardiovascular risk factors (eg, cessation of smoking and other lifestyle changes, sleep hygiene, and pharmacotherapy), and prescription of a regimen of narcolepsy medications that balances symptomatic benefits with cardiovascular safety.

1 April 2015 in Nature and Science of Sleep
Verified
Journal Article
Open access
PJPoul Jennum
Poul Jennum
PTPhilip Tønnesen
Philip Tønnesen
RIRikke Ibsen
Rikke Ibsen
JKJakob Kjellberg
Jakob Kjellberg
Background: More information is needed about the effect on mortality of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA), especially in women. Methods: We employed a historical cohort study design, using data from 25,389 patients with a diagnosis of OSA selected from the Danish National Patient Registry for the period 1999–2009. We used Cox proportional hazard function to evaluate the all-cause mortality from OSA in middle-aged and elderly males and females who were treated, or not, with CPAP. Results: Female OSA patients had a lower mortality than males, irrespective of whether they received CPAP treatment. CPAP treatment improved survival, as illustrated by the hazard ratio of 0.62 (P<0.001). This effect was dependent on gender: CPAP had no significant effect on 20- to 39-year-old males and females, but the overall mortality in this age group was small. Survival was increased by CPAP in 40- to 59-year-old and ≥60-year-old males, but no such effect was observed in females. Positive predictors of survival were young age, female gender, higher educational level, and low 3-year prior comorbidity as estimated by the Charlson Comorbidity Index. Negative predictors for survival were male gender, age ≥60 years, no CPAP treatment, prior comorbidity, and low educational level. Conclusion: CPAP therapy is associated with reduced all-cause mortality in middle-aged and elderly males, but no significant effect was found in females.

1 June 2015 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
PJPoul Jennum
Poul Jennum
HIHelle Klingenberg Iversen
Helle Klingenberg Iversen
RIRikke Ibsen
Rikke Ibsen
JKJakob Kjellberg
Jakob Kjellberg
To estimate the direct and indirect costs of stroke in patients and their partners. Direct and indirect costs were calculated using records from the Danish National Patient Registry from 93,047 ischemic, 26,012 hemorrhagic and 128,824 unspecified stroke patients and compared with 364,433, 103,741 and 500,490 matched controls, respectively. Independent of age and gender, stroke patients had significantly higher rates of mortality, health-related contacts, medication use and lower employment, lower income and higher social-transfer payments than controls. The attributable cost of direct net health care costs after the stroke (general practitioner services, hospital services, and medication) and indirect costs (loss of labor market income) were €10,720, €8,205 and €7,377 for patients, and €989, €1,544 and €1.645 for their partners, over and above that of controls for hemorrhagic, ischemic and unspecified stroke, respectively. The negative social- and health-related status could be identified up to eleven years before the first diagnosis. Stroke has significant mortality, morbidity and socioeconomic consequences for patients, their partners and society.

20 June 2016 in Epilepsia
Verified
Journal Article
Closed access
PDF file
PJPoul Jennum
Poul Jennum
JCJakob Christensen
Jakob Christensen
RIRikke Ibsen
Rikke Ibsen
JKJakob Kjellberg
Jakob Kjellberg

1 January 2019 in Journal of Comorbidity
Verified
Journal Article
Open access
PDF file
KLKatrine Løppenthin
Katrine Løppenthin
BEBente Appel Esbensen
Bente Appel Esbensen
MØMikkel Østergaard
Mikkel Østergaard
RIRikke Ibsen
Rikke Ibsen
JKJakob Kjellberg
Jakob Kjellberg
PJPoul Jennum
Poul Jennum
Objective: The aim of this study was to examine the prevalence of morbidity and mortality in patients with seropositive rheumatoid arthritis (RA). Methods: Data were obtained from national population-based registries in the period 1998–2009. Prior to the seropositive RA diagnosis (International Classification of Disorders 10th revision M05), we identified a total of 21,558 patients and 87,384 age- and sex-matched control subjects. Odds for morbidity were calculated before and after the RA diagnosis. We estimated the overall survival based on the Kaplan–Meier method. Results: Patients with RA had statistically significantly higher odds for a number of co-morbidities prior to the onset of RA including diseases of the musculoskeletal system (odds ratio (OR) 3.10, 95% confidence interval (CI) 3.00–3.21), diseases involving the immune system (OR 1.45, 95% CI 1.29–1.64), endocrine diseases (OR 1.09, 95% CI 1.01–1.17), diseases of the circulatory system (OR 1.08, 95% CI 1.03–1.14) and diseases of the respiratory system (OR 1.30, 95% CI 1.22–1.38), compared with age- and sex-matched control subjects. After the RA diagnosis, the same trend was seen with higher odds for the same co-morbidities. We found a 5-year survival of 80% (95% CI 78–81%) for patients with RA, while for control subjects it was 88% (95% CI 88–89%). Conclusion: Compared with age- and sex-matched controls, patients with seropositive RA have higher odds for several co-morbidities prior to and, particularly, after the diagnosis of RA. Furthermore, patients with RA have a lower overall survival compared with age- and sex-matched controls.

1 January 2021 in Sleep Medicine
Verified
Journal Article
Closed access
Matteo  CesariMatteo Cesari
Matteo Cesari
JCJulie A.E. Christensen
Julie A.E. Christensen
MMMaria-Lucia Muntean
Maria-Lucia Muntean
BMBrit Mollenhauer
Brit Mollenhauer
FSFriederike Sixel-Döring
Friederike Sixel-Döring
PJPoul Jennum
Poul Jennum